These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31044248)

  • 1. HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era.
    Nápoles TM; Batchelder AW; Lin A; Moran L; Johnson MO; Shumway M; Luetkemeyer AF; Peters MG; Eagen KV; Riley ED
    J Public Health (Oxf); 2019 Dec; 41(4):e283-e289. PubMed ID: 31044248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment.
    Brothers S; DiDomizio E; Nichols L; Brooks R; Villanueva M
    AIDS Behav; 2023 Jan; 27(1):119-133. PubMed ID: 35776253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
    Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals.
    Nitulescu R; Young J; Saeed S; Cooper C; Cox J; Martel-Laferriere V; Hull M; Walmsley S; Tyndall M; Wong A; Klein MB;
    Int J Drug Policy; 2019 Mar; 65():41-49. PubMed ID: 30594080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy.
    Taylor LE; Swan T; Matthews GV
    Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S118-24. PubMed ID: 23884059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
    Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
    Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Utilization of Direct-Acting Antiviral Agents in a Large National Cohort of HIV and HCV Coinfected Medicare Patients in the United States: Implications for HCV Elimination.
    Du P; Jung J; Kalidindi Y; Farrow K; Riley T; Whitener C
    J Public Health Manag Pract; 2022 Mar-Apr 01; 28(2):130-134. PubMed ID: 32011599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers to hepatitis C direct-acting antiviral therapy among HIV/hepatitis C virus-coinfected persons.
    Jatt LP; Gandhi MM; Guo R; Sukhija-Cohen A; Bhattacharya D; Tseng CH; Chew KW
    J Gastroenterol Hepatol; 2021 Apr; 36(4):1095-1102. PubMed ID: 32840904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "I'm obviously not dying so it's not something I need to sort out today": Considering hepatitis C treatment in the era of direct acting antivirals.
    Wright C; Cogger S; Hsieh K; Goutzamanis S; Hellard M; Higgs P
    Infect Dis Health; 2019 May; 24(2):58-66. PubMed ID: 30541692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.
    Sacks-Davis R; Doyle JS; Rauch A; Beguelin C; Pedrana AE; Matthews GV; Prins M; van der Valk M; Klein MB; Saeed S; Lacombe K; Chkhartishvili N; Altice FL; Hellard ME
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25051. PubMed ID: 29633559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic HCV genotype 1 coinfection.
    Boesecke C; Rockstroh JK
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs.
    Socías ME; Ti L; Dong H; Shoveller J; Kerr T; Montaner J; Milloy MJ
    HIV Med; 2017 Oct; 18(9):647-654. PubMed ID: 28294492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions.
    Chan J; Chung RT
    Clin Pharmacol Drug Dev; 2017 Mar; 6(2):147-163. PubMed ID: 28263458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing Persons With HIV/HCV Coinfection Who Remain Untreated for Hepatitis C at Four HIV Clinics in Connecticut (CT): Role of Multiple Overlapping Barriers at the Individual and Clinic System Levels.
    Zhao A; Wegener M; Brooks R; Mininberg L; Helou E; Maughan A; Villanueva M
    Health Promot Pract; 2023 Sep; 24(5):1029-1038. PubMed ID: 37439687
    [No Abstract]   [Full Text] [Related]  

  • 15. Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection.
    Allyn PR; O'Malley SM; Ferguson J; Tseng CH; Chew KW; Bhattacharya D
    Int J STD AIDS; 2018 Mar; 29(4):334-340. PubMed ID: 28820346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
    Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
    BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of acute and chronic HCV infection in persons with HIV coinfection.
    Sulkowski MS
    J Hepatol; 2014 Nov; 61(1 Suppl):S108-19. PubMed ID: 25443339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interactions of hepatitis C direct-acting antivirals in the HIV-infected person.
    El-Sherif O; Back D
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):336-43. PubMed ID: 26159742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands.
    Boerekamps A; Newsum AM; Smit C; Arends JE; Richter C; Reiss P; Rijnders BJA; Brinkman K; van der Valk M;
    Clin Infect Dis; 2018 Apr; 66(9):1352-1359. PubMed ID: 29186365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
    Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
    Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.